Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine.
暂无分享,去创建一个
[1] A. Shinagare,et al. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients , 2016, Abdominal Radiology.
[2] P. D. Dal Cin,et al. Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. , 2015, Surgical pathology clinics.
[3] T. Choueiri,et al. Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma , 2015, Cancer Immunology Research.
[4] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[5] G. Gibney,et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.
[6] S. Signoretti,et al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma , 2015, Cancer.
[7] J. Cheville,et al. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Hoffman,et al. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma , 2015, Cancer Imaging.
[9] Matthew A. Zapala,et al. The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. , 2015, Radiology.
[10] B. K. Park,et al. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. , 2015, The British journal of radiology.
[11] F. Hodi,et al. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. , 2015, The New England journal of medicine.
[12] F. Hodi,et al. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab , 2015, Cancer Immunology Research.
[13] W. Shabana,et al. Diagnosis of Sarcomatoid Renal Cell Carcinoma With CT: Evaluation by Qualitative Imaging Features and Texture Analysis. , 2015, AJR. American journal of roentgenology.
[14] A. Shinagare,et al. Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.
[15] Erich P Huang,et al. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas–Renal Cell Carcinoma (TCGA–RCC) Imaging Research Group , 2015, Abdominal Imaging.
[16] J. Larkin,et al. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. , 2014, Radiology.
[17] A. D. Van den Abbeele,et al. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. , 2014, The oncologist.
[18] J. Wolchok,et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.
[19] J. Manola,et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. , 2014, European journal of cancer.
[20] M. Kuo,et al. Behind the numbers: Decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations. , 2014, Radiology.
[21] D. Berney,et al. Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma , 2013, British Journal of Cancer.
[22] E. Jonasch,et al. The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma , 2013, American journal of clinical oncology.
[23] H. Hricak,et al. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. , 2013, Radiology.
[24] Blanca Paño Brufau,et al. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.
[25] Lars Egevad,et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia , 2013, The American journal of surgical pathology.
[26] M. P. Hayball,et al. CT texture analysis using the filtration-histogram method: what do the measurements mean? , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.
[27] A. Shinagare,et al. Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[28] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[29] V. Goh,et al. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy , 2013, British Journal of Cancer.
[30] A. Shinagare,et al. Liver metastases in the era of molecular targeted therapy: new faces of treatment response. , 2013, AJR. American journal of roentgenology.
[31] A. Giobbie-Hurder,et al. Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.
[32] A. Shinagare,et al. Ipilimumab-associated colitis: CT findings. , 2013, AJR. American journal of roentgenology.
[33] K. Flaherty,et al. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. , 2013, AJR. American journal of roentgenology.
[34] A. Shinagare,et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. , 2012, AJR. American journal of roentgenology.
[35] J. Jagannathan,et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know. , 2012, AJR. American journal of roentgenology.
[36] W. Rathmell,et al. Renal Cell Carcinoma , 2012, Springer US.
[37] Christian Rothermundt,et al. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies , 2012, European Radiology.
[38] A. Ravaud,et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] Qian Wang,et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. Cuénod,et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study. , 2012, European journal of cancer.
[41] I. Pedrosa,et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. , 2012, European journal of cancer.
[42] U. Tateishi,et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course , 2012, BMC Cancer.
[43] K. Flaherty,et al. From genes to drugs: targeted strategies for melanoma , 2012, Nature Reviews Cancer.
[44] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[45] A. Ravaud,et al. Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year , 2012, Current Urology Reports.
[46] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[47] J. Vauthey,et al. CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. , 2011, AJR. American journal of roentgenology.
[48] A. D. Van den Abbeele,et al. Hereditary cancer syndromes: a radiologist's perspective. , 2011, AJR. American journal of roentgenology.
[49] V. Goh,et al. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.
[50] W. Kaelin,et al. New insights into the biology of renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.
[51] F. Hodi,et al. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. , 2011, AJR. American journal of roentgenology.
[52] R. Motzer,et al. mTOR inhibitors in advanced renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.
[53] Peter N. Burns,et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. , 2011, Radiology.
[54] T. Choueiri,et al. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. , 2011, Hematology/oncology clinics of North America.
[55] T. Powles,et al. Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.
[56] T. Choueiri,et al. Everolimus- and temsirolimus-associated enteritis: report of three cases. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] E. Van Cutsem,et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Ivan Pedrosa,et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. , 2011, European Urology.
[59] J. Maroto,et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Zucman‐Rossi,et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] Shenhong Wu,et al. Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis , 2010, Oncology.
[62] Gilles Chatellier,et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. , 2010, Radiology.
[63] Shetal N Shah,et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. , 2010, AJR. American journal of roentgenology.
[64] T. Choueiri,et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] L. Trinquart,et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] S. Koscielny,et al. Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography , 2010, Clinical Cancer Research.
[67] Vicky Goh,et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.
[68] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[69] T. Choueiri,et al. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2009, The Lancet. Oncology.
[70] J. Blay,et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] W. Linehan,et al. Targeting the Met signaling pathway in renal cancer , 2009, Expert review of anticancer therapy.
[72] R. Vikram,et al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[73] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[74] Gregory Karczmar,et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] Ivan Pedrosa,et al. Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.
[76] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[77] W. Kaelin,et al. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.
[78] K. Flaherty,et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.
[79] D. Fisher,et al. MiT Transcription Factor Associated Malignancies in Man , 2007, Cell cycle.
[80] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[81] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Cheville,et al. PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[83] M. Ladanyi,et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.
[84] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[85] R. Motzer,et al. Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] Linda Chami,et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.
[87] Robert E. Brown,et al. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. , 2006, Annals of clinical and laboratory science.
[88] R. Motzer,et al. Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.
[89] J. Cheville,et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.
[90] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] G. Jakse,et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. , 2003, Cancer research.
[92] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[93] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[94] W. Linehan,et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.
[95] F. Mostofi,et al. Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy , 1995, The American journal of surgical pathology.
[96] Y Kubota,et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.
[97] E. van den Berg,et al. Cytogenetic analysis of epithelial renal‐cell tumors: Relationship with a new histopathological classification , 1993, International journal of cancer.
[98] D. Sargent,et al. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. , 2014, European journal of cancer.
[99] A. Rabinstein,et al. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. , 2012, QJM : monthly journal of the Association of Physicians.
[100] Shetal N Shah,et al. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. , 2010, AJR. American journal of roentgenology.
[101] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[102] A. Ravaud,et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.